Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAP2 | P11137 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081314 | 0.84 | RAB9A (0.41) | ADAMTS5NPC1LMNATP53MAPK1 | |
| SCHEMBL2995871 | 0.77 | CYP11B2 (0.38) | NPC1LMNATP53MAPK1RAB9A | |
| SCHEMBL3546618 | 0.75 | MAPT (0.55) | NPC1LMNATP53MAPK1RAB9A | |
| SCHEMBL989945 | 0.72 | HTR3A (0.43) | RAB9ACCNT1CDK4CCND1CDK9 | |
| SCHEMBL992615 | 0.70 | HTR3A (0.43) | RAB9APTK2 | |
| SCHEMBL3549535 | 0.70 | SIRT6 (0.62) | MAPK1ALDH1A1 | |
| SCHEMBL3547211 | 0.70 | HDAC3 (0.44) | NPC1LMNATP53MAPK1RAB9A | |
| SCHEMBL2370707 | 0.69 | NPC1 (0.56) | NPC1LMNATP53RAB9AKMT2A | |
| SCHEMBL23293931 | 0.69 | PARP1 (0.45) | NPC1MAPK1RAB9AKMT2AKDM4E | |
| SCHEMBL989799 | 0.69 | SIRT6 (0.41) | LMNAMAPK1ALDH1A1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-7534808-B2 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2009-05-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | EVENOU JEAN-PIERRE | 2008-05-08 | — | — | US | disclosed |
| US-7358253-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2008-04-15 | — | — | US | disclosed |
| US-7235555-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-06-26 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20070032507-A1 | Indolylmaleimide derivatives | ELANCO TIERGESUNDHEIT AG (CH) | 2007-02-08 | — | — | US | disclosed |
| US-20050119274-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1490355-A1 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082859-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032507-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | ADAMTS5 744/4885NPC1 3340/4885LMNA 3154/4885 |
| US-20080108628-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug | NFATC1, CD4, LCK | ADAMTS5 1700/4885NPC1 2401/4885LMNA 4455/4885 |
| US-20050119274-A1 | Indolylmaleimide derivatives | MYLK2, DGKK, LCK | ADAMTS5 744/4885NPC1 3340/4885LMNA 3154/4885 |
| US-20080146578-A1 | INDOLYLMALEIMIDE DERIVATIVES | MYLK2, LCK, DGKK | ADAMTS5 731/4885NPC1 3230/4885LMNA 2939/4885 |
| US-20070037826-A1 | Treatment of diseases or disorders mediated by T lymphocytes and/or PKC, e.g., acute or chronic rejection of organ or tissue allo- or xenografts or graft versus host disease | DGKK, DGKG, HLA-DRB1 | ADAMTS5 431/4885NPC1 2503/4885LMNA 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.